Novavax vaccine
The National Advisory Committee on Immunization continues to strongly recommend the use of mRNA COVID-19 vaccines (e.g., Moderna, Pfizer) due to the excellent protection they provide against severe illness and hospitalization. Novavax vaccine is a recombinant protein subunit COVID-19 vaccine that may be offered as a primary series to those 12 years of age or older who are not able or willing to receive an mRNA COVID-19 vaccine. A primary series of Novavax is two doses.
Novavax may be offered as a booster dose to people who are not willing or not able to receive an mRNA vaccine, regardless of which COVID-19 vaccines they may have already received. Novavax may be offered as a booster dose in people 18 years and older.
Resources
-
Summary of National Advisory Committee on Immunization (NACI) Statement - Public Health Agency of Canada
- Novavax Nuvaxovid COVID-19 vaccine - Government of Canada